ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D., Vice President of R&D, will speak at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference being held May 15-16, 2023…


Previous articlePsychedelics Weekly – The Church of Psilomethoxin Controversy, Psychedelics for Long COVID, and The Growth of Bicycle Day
Next articleBetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California